Microsoft word - other studies.docx

Liver tumours: hepatic adenomasand hepatocarcinoma [8] Overly WL, Dankoff JA, Wang BK, Singh UD. Androgens and hepatocellular carcinoma in an athlete. Ann [9] Goldman B. Liver carcinoma in an athlete taking anabolic steroids. J Am Osteopath Assoc 1985;85:56. [11] Creagh TM, Rubin A, Evans DJ. Hepatic tumours induced by anabolic steroids in an athlete. J Clin [17] Bagia S, Hewitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust N Z J Surg 2000;70:686–7. [18] Snyder PJ. Androgens. In: Brunton LL, Lazo JS, Parker KL, editors. The pharmacological basis of therapeutics. 11th ed. New York: Goodman & Gilman’s; 2005. p. 1573–85 [Chapter 58]. [20] Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005;39:e27. [21] George AJ. Androgenic anabolic steroids. In: Mottram DR, editor. Drugs in sport. 4th ed. London: Mottram DR; 2006. p. 140–85 [Chapter 5]. Renal tumours: nephroblastoma and renal cell carcinoma [7] Prat J, Gray GF, Stolley PD, Coleman JW. Wilms tumor in an adult associated with androgen abuse. [12] Bryden AA, Rothwell PJ, O’Reilly PH. Anabolic steroid abuse and renalcell carcinoma. Lancet [15] Martorana G, Concetti S, Manferrari F, Creti S. Anabolic steroid abuse and renal cell carcinoma. J Urol [19] Parssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Med [10] Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet [13] Street C, Antonio J, Cudlipp D. Androgen use by athletes: a reevaluation of the health risks. Can J Appl [14] Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B, Wirth MP. Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol. A case report. Cancer 1999;86:1571–5. [16] Parssinen M,Kujala U,Vartiainen E, Sarna S, SeppalaT. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000;21:225–7. [59] Magnavita N, Teofili L, Leone G. Hodgkin’s lymphoma in a cyclist treated with growth hormone. Am J B. Clinical studies on AS, GH/IGF-1, Epo and risk of cancer Long-term AS therapy, high serum androgen levels: [18] Snyder PJ. Androgens. In: Brunton LL, Lazo JS, Parker KL, editors. The pharmacological basis of therapeutics. 11th ed. New York: Goodman & Gilman’s; 2005. p. 1573–85 [Chapter 58]. [31] George AJ. Peptide and glycoprotein hormones and sport. In: Mottram DR, editor. Drugs in sport. 4th ed. London: Mottram DR; 2006. p. 191–204 [Chapter 6]. [75] Velazquez I, Alter BP. Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions. Am [81] Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 2005;97:755–65. [24] Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17:421–4. [25] Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A:492–7. [26] Hankinson SE,Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393–6. [27] Chan JM, Stampfer MJ, Giovannucci E, Gann PH,MaJ,Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563–6. [28] Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case–control study. J Natl Cancer Inst 1999;91:151–6. [29] Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl [46] Swerdlow AJ. Does growth hormone therapy increase the risk of cancer? Nat Clin Pract Endocrinol [58] Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 2002;360:273–7. [60] Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004;144:430–6. [61] Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol [58] Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 2002;360:273–7. rEpo to prevent or treat malignancy-associated anaemia: Dubious impact on progression-free survival time [107] Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo-controlled [108] Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin a in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–72. [109] Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708–13. [110] Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1 h infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689–97. [111] Michael U, Jackisch C, Lenhard MS, Du Bois A, Lueck H, Thomssen C, et al. Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC). 41st Annual Meeting of the American Society of Clinical Oncology, May 13–17, 2003. J Clin Oncol 2005;23:613 [Abstract]. [112] Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J [113] Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R. Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervial cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. 29th European Society for Medical Oncology Congress, 29 October to 2 November 2004. Ann Oncol 2004;15(Suppl. 3):447PD

Source: http://asada.govspace.gov.au/files/2012/05/Other-Studies1.pdf